Editors' Pick Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue E-W, Stefoski D, Robinson R, Riester K, Rana J, et al. Lancet. 2013 Apr 3. Epub 1969 Dec 31. PMID: 23562009. Abstract CommentRecommendBookmarkWatch